key: cord-0733819-my1nfea6
authors: Shaker, Marcus; Phillips, Elizabeth; Blumenthal, Kimberly G.; Abrams, Elissa M.; Banerji, Aleena; Oppenheimer, John; Vander Leek, Timothy K.; Mack, Douglas P.; Wickner, Paige G.; Singer, Alexander G.; Khan, David A.; Greenhawt, Matthew
title: The importance of a timely second dose of the 2021 COVID-19 mRNA vaccine depends on the protection afforded by a first dose and subsequent risk of anaphylaxis
date: 2021-04-20
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.04.015
sha: a095d4539abdf42dd0db7bb46c8c14b3eae8fbf9
doc_id: 733819
cord_uid: my1nfea6

Vaccination against SARS-CoV-2 represents our greatest hope to combat the devastating COVID-19 pandemic. Amidst ongoing global vaccination efforts, rare cases of severe allergic reactions to COVID-19 mRNA vaccines have received significant attention. Although the exact nature of these reactions may be heterogeneous, various approaches exist to engage with patients, communities, public health departments, primary care providers, and other clinicians in a multidisciplinary approach to advance population health. While it is optimal for patients to receive COVID-19 vaccination as outlined in emergency use authorizations, second dose deferral of mRNA vaccines may be a consideration within a shared decision-making paradigm of care in select circumstances characterized by high durable first vaccine dose protection and significant elevations of vaccine anaphylaxis risk. Still, the durability of protection afforded by a single dose of a COVID-19 mRNA vaccine is uncertain, and alternative approaches to complete vaccination, including precautionary use of a COVID-19 viral vector vaccine, also remain patient preference sensitive options. There is an urgent need to define correlates of COVID-19 immunity and the level of longer-term protection afforded by COVID-19 vaccination.

Vaccination against SARS-CoV-2 represents our greatest hope to combat the devastating 70 COVID-19 pandemic. Amidst ongoing global vaccination efforts, rare cases of severe allergic 71 reactions to COVID-19 mRNA vaccines have received significant attention. Although the exact 72 nature of these reactions may be heterogeneous, various approaches exist to engage with 73 patients, communities, public health departments, primary care providers, and other clinicians 74 in a multidisciplinary approach to advance population health. While it is optimal for patients to 75 receive COVID-19 vaccination as outlined in emergency use authorizations, second dose 76 deferral of mRNA vaccines may be a consideration within a shared decision-making paradigm of 77 care in select circumstances characterized by high durable first vaccine dose protection and 78 significant elevations of vaccine anaphylaxis risk. Still, the durability of protection afforded by a 79 single dose of a COVID-19 mRNA vaccine is uncertain, and alternative approaches to complete 80 vaccination, including precautionary use of a COVID-19 viral vector vaccine, also remain patient 81 preference sensitive options. There is an urgent need to define correlates of immunity and the level of longer-term protection afforded by J o u r n a l P r e -p r o o f

Within the context of a rapidly mobilizing global vaccination effort to combat 85 questions have emerged regarding whether or not to proceed with a timely second COVID-19 86 mRNA vaccine dose for individuals who have had a potential allergic reaction to a first dose.(1-87 4) While guidance has evolved, as of this writing the Centers for Disease Control (CDC) 88 considers a severe allergic reaction after a previous dose of a COVID-19 mRNA vaccine a 89 contraindication to future administration of a COVID-19 mRNA vaccine, and suggests evaluation 90 with an allergist-immunologist for patients with immediate allergic reactions of any severity to 91 an mRNA vaccine.(5) Furthermore, the CDC advises that if delays in administering the second 92 dose are unavoidable, the Pfizer-BioNtech and Moderna COVID-19 mRNA vaccines can be 93 administered up to 6 weeks following the initial dose. (5) 94 95 Ultimately, whether to provide or defer a second mRNA vaccine dose in patients at risk for 96 anaphylaxis to a COVID-19 mRNA vaccine warrants an approach grounded in shared decision-97 making, as this is a highly preference-sensitive care option given current data.(6-8) While the 98 allergist-immunologist engages the patient in shared decision-making, it is important that the 99 clinician guard against a tendency toward risk aversion to "first, do no harm", particularly given 100 COVID-19 mRNA first-dose effectiveness estimates range from 46% to 93% among various 101 studies with uncertain duration of immunity. (3, 4, (9) (10) (11) (12) (13) (14) While the risk of anaphylaxis is real, it 102 is easy to lose sight of the forest for the trees while striving for nonmaleficence through second 103 dose deferral, and actually place a patient at greater risk for disease morbidity in the long 104 term.(15) Furthermore, it is quite possible for the allergist-immunologist to inadvertently 105 patient's own values with that of the clinician.(8-10) Our specialty has a checkered past in trying 107 to attenuate risk of anaphylaxis in the short term while sacrificing long term health benefits, 108 and we need not look far to find obvious examples, which range from overdiagnosis of 109 anaphylaxis risk to vaccines, foods, and medications. follow-up has been limited for single dose recipients, and this may represent an upper limit of 117 protection that in reality could be much lower.(1-4, 11) The question of whether to delay the 118 second dose of these vaccines to facilitate more rapid dissemination of first vaccine doses has 119 been an area of debate, even in patients without a prior reaction to a first dose.(2) At present, 120 concern remains that deviating from recommended intervals could lead to a suboptimal 121 vaccine immune response. In weighing the risk versus benefit, could a management strategy consisting of deferral of the 131 second dose of a COVID-19 mRNA vaccine in those with significantly increased anaphylaxis risk 132 be a reasonable option for some? Answering such a question relies on several theoretical 133 assumptions. Decisional modeling is possible if we presume durable immunity lasting at least 12 134 months from vaccination following a single mRNA vaccine dose and maintain the efficacy rates 135 attributed to the COVID-19 mRNA vaccines from publications supporting emergency use. 136

Adapting a previously published health-economic model of risk-stratification strategies relative 137 to COVID-19 mRNA vaccine anaphylaxis to evaluate anaphylaxis-risk thresholds for deferral of a 138 second dose of these vaccines reveals interesting findings (Table 1 ).(23) Assuming a very high 139 rate of first dose durable protection of 90% against symptomatic COVID-19 infection over the 140 ensuing year with a 5% additional second dose benefit, deferring a second dose would be cost-141 effective if anaphylaxis risk exceeds 0.13% (1,300 anaphylaxis cases/million vaccinations; 142 willingness to pay threshold of $10,000,000 per death prevented). While a 0.13% risk is quite 143 low when considering second dose risk in a patient with a convincing history of anaphylaxis to a 144 first dose, it is well above the currently reported population risk (2.5 to 11.1 anaphylaxis cases 145 per million) for COVID-19 mRNA vaccines.(24, 25) Furthermore, the durability of first (or even 146 second) dose protection is uncertain, and it should be noted that if either the durable 147 immunologic protection of a first vaccine dose falls (an assumption that may be more 148 J o u r n a l P r e -p r o o f realistic),(11) or the overall vaccine efficacy against COVID-19 (and present and future variants 149 in the next year) decreases,(26) the anaphylaxis-risk threshold for second vaccine dose deferral 150 of an mRNA vaccine rises from 0.13% to an upper limit of 6.05-21.72% across estimates of 151 overall vaccine protection (6,005-21,720 anaphylaxis cases/million; Table 1) Allergists-immunologists must continue to partner with patients and multidisciplinary 239 healthcare providers to discuss the knowns and the unknowns and weigh the benefits and risks 240 of approaches to vaccination. The ultimate goals of optimizing individual and population health 241 outcomes need to be prioritized. As we enter these discussions, we must remember the three 242 conversations of effective shared decision-making -team talk to outline patient goals and 243 preferences, option talk to clarify choices, and decision talk to reach preference- COVID-19 immunization appears to be exceptionally rare, with over 458 million doses given to 293 date. (28, 47, 48) In the months to come the continued emergence of SARS-CoV-2 variants may 294 pose challenges to vaccination strategies.(26) There will also be the benefit of additional 295 COVID-19 vaccines being granted EUA in the United States.(34) As we continue to provide each 296 patient the right care at the right time, new discoveries will continue to allow insights that will 297 shape and optimize our practice. While we are accumulating this evidence base, our ultimate 298 goal must be to avoid unnecessary vaccine hesitancy and deferral and to optimize both vaccine 299 acceptance and efficacy, while safely vaccinating the world. 300 301 J o u r n a l P r e -p r o o f This table demonstrates the anaphylaxis risk threshold projected using different modeled scenarios considering efficacy of the first dose and increase in second dose protection against symptomatic COVID-19 infection. The degree to which first and second dose offer protection to other contacts of the vaccinee was not specifically modeled and could increase the anaphylaxis threshold at which second dose deferral would be cost-effective. *Evaluation of costeffectiveness threshold (willingness to pay: $10,000,000 per death prevented) of anaphylaxis risk for a second dose of an mRNA COVID-19 vaccination from a societal perspective. Anaphylaxis risk threshold represents the value at which second vaccine deferral is cost-effective in an at-risk population who has received some degree of durable protection from a first vaccination for the ensuing 12 months.

J o u r n a l P r e -p r o o f c. Defer 2 nd dose Administer 2 nd dose

How important is the second dose of the COVID-19 mRNA vaccine? The Journal of 303 Allergy and Clinical immunology in Practice

Delayed Second Dose versus Standard Regimen for Covid-19 305 Vaccination

Early rate reductions of SARS-CoV-2 308 infection and COVID-19 in BNT162b2 vaccine recipients

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Centers for Disease Control and Prvention. Interim Clinical Considerations for Use of 313 mRNA COVID-19 Vaccines Currently Authorized in the United States

The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely 319 Vaccinating the World

mRNA Vaccines 321 to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested 322 Approach

The 324 Challenges and Opportunities for Shared Decision Making Highlighted by COVID-19

Engaging patient partners in state-of-the-art 327 allergy care: Finding balance when discussing risk

Risk Communication During COVID-19

BNT162b2 mRNA Covid-332 19 Vaccine in a Nationwide Mass Vaccination Setting

Safety and 334 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of 336 the mRNA-1273 SARS-CoV-2 Vaccine

338 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

What the COVID-19 Pandemic Can 341 Teach Us About Resource Stewardship and Quality in Health Care

To screen or not 344 to screen": Comparing the health and economic benefits of early peanut introduction strategies 345 in five countries

Delabeling penicillin allergy: Is skin testing required at all? 347

Administration of influenza vaccines to egg allergic 349 recipients: A practice parameter update 2017

The Cost of Penicillin 352 Allergy Evaluation

The Impact of a Reported 354

Vaccines and Related Biological Products Advisory Committee meeting

Effect of previous 359 SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation

Hospitalizations, Fatalities, and Economic Outcomes Associated With Universal Versus 364

Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

Allergic reactions 367 including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -368 United States

Allergic reactions 371 including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine

Serum 375 Neutralizing Activity Elicited by mRNA-1273 Vaccine -Preliminary Report

A primer on cost-effectiveness in the allergy clinic

Reports of Anaphylaxis After Receipt of mRNA COVID-19

Adverse 382 reactions to vaccines practice parameter 2012 update

VAccine Anaphylaxis

ARIA-EAACI 388 statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA position paper

American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic 392 Reactions to mRNA SARS-CoV-2 Vaccines

ACIP COVID-19 Vaccines Work Group. Clinical Considerations for Use of COVID-19

FDA US Food and Drug Administration Janssen Biotech Emergency Use Authorization

Poly(ethylene glycol)s generate 401 complement activation products in human serum through increased alternative pathway 402 turnover and a MASP-2-dependent process

Recognition of 404 single-stranded RNA viruses by Toll-like receptor 7. Proceedings of the National Academy of 405 Sciences of the United States of America

Activation of mast cells by double-407 stranded RNA: evidence for activation through Toll-like receptor 3

COVID-19 410 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis 411 Committee

Activation of complement by therapeutic 413 liposomes and other lipid excipient-based therapeutic products: prediction and prevention. 414 Advanced drug delivery reviews

CNN. Fauci urges vaccinations to stop new virus strains: "viruses cannot mutate if they 418 don't replicate

J&J CEO says people may need annual COVID vaccine shots for the next several years 421

COVID-19 Vaccine Allergy Case Registry

Patient 426 Characteristics and Concerns about Drug Allergy: A Report from the United States Drug Allergy 427 Registry

More Than 458 Million Shots Given: Covid-19 Tracker